An effort to improve the collection of patient-generated data: readability and understandability of patient-reported outcomes measures in a survivorship cohort.

PROMs PROs Patient-reported outcome measures Readability Survivorship Understandability

Journal

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257

Informations de publication

Date de publication:
05 Mar 2024
Historique:
accepted: 01 01 2024
medline: 5 3 2024
pubmed: 5 3 2024
entrez: 5 3 2024
Statut: aheadofprint

Résumé

In this study, we evaluated readability and understandability of nine French-language Patient-Reported Outcome Measures (PROMs) that are currently used in a contemporary longitudinal cohort of breast cancer survivors as part of an effort to improve equity in cancer care and research. Readability of PROMs was assessed using the Flesh Reading Ease Score (FRES), the Gunning's Fog Index (FOG), and the FRY graphics. Readability was considered ideal if mean score ≤ 6th-grade level and acceptable if between 6th and 8th grade. Understandability was evaluated using the Patient Education Materials Assessment Tool and defined as ideal if PEMAT ≥ 80%. The Evaluative Linguistic Framework for Questionnaires (ELF-Q) provided additional qualitative elements to assess understandability. Plain-language best practice was met if both readability and understandability were ideal. None of the 9 PROMs evaluated had ideal readability scores and only 1 had an acceptable score. Understandability ranged from 55% to 91%, and only 3 PROMs had ideal scores. ELF-Q identified points for improvement in several understandability dimensions of the PROMs. None of the instruments met the definition of plain-language best practice. None of the studied PROMs met the standards of readability and understandability. Future development and translation of PROMs should follow comprehensive linguistic and cultural frameworks to ensure plain-language standards and enhance equitable patient-centered care and research.

Identifiants

pubmed: 38441716
doi: 10.1007/s11136-024-03600-8
pii: 10.1007/s11136-024-03600-8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Références

Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17–48. https://doi.org/10.3322/caac.21763
doi: 10.3322/caac.21763 pubmed: 36633525
Cancer Statistics Review, 1975–2012 – Previous Version – SEER Cancer Statistics Review. In: SEER. https://seer.cancer.gov/archive/csr/1975_2012/index.html . Accessed 22 Feb 2023.
Ferreira, A. R., Meglio, A. D., Pistilli, B., et al. (2019). Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: A prospective patient-reported outcomes analysis. Annals of Oncology, 30, 1784–1795. https://doi.org/10.1093/annonc/mdz298
doi: 10.1093/annonc/mdz298 pubmed: 31591636
Dumas, A., Vaz Luis, I., Bovagnet, T., et al. (2020). Impact of breast cancer treatment on employment: Results of a multicenter prospective cohort study (CANTO). Journal of Clinical Oncology, 38, 734–743. https://doi.org/10.1200/JCO.19.01726
doi: 10.1200/JCO.19.01726 pubmed: 31834818
Firkins, J., Hansen, L., Driessnack, M., & Dieckmann, N. (2020). Quality of life in “chronic” cancer survivors: A meta-analysis. Journal of Cancer Survivorship, 14, 504–517. https://doi.org/10.1007/s11764-020-00869-9
doi: 10.1007/s11764-020-00869-9 pubmed: 32162194
Pinto, A. C., & de Azambuja, E. (2011). Improving quality of life after breast cancer: Dealing with symptoms. Maturitas, 70, 343–348. https://doi.org/10.1016/j.maturitas.2011.09.008
doi: 10.1016/j.maturitas.2011.09.008 pubmed: 22014722
Hamer, J., McDonald, R., Zhang, L., et al. (2017). Quality of life (QOL) and symptom burden (SB) in patients with breast cancer. Supportive Care in Cancer, 25, 409–419. https://doi.org/10.1007/s00520-016-3417-6
doi: 10.1007/s00520-016-3417-6 pubmed: 27696078
Jim, H. S. L., Hoogland, A. I., Brownstein, N. C., et al. (2020). Innovations in research and clinical care using patient-generated health data. CA: A Cancer Journal for Clinicians, 70, 182–199. https://doi.org/10.3322/caac.21608
doi: 10.3322/caac.21608 pubmed: 32311776
Atkinson, T. M., Li, Y., Coffey, C. W., et al. (2012). Reliability of adverse symptom event reporting by clinicians. Quality of Life Research, 21, 1159–1164. https://doi.org/10.1007/s11136-011-0031-4
doi: 10.1007/s11136-011-0031-4 pubmed: 21984468
Basch, E., Iasonos, A., McDonough, T., et al. (2006). Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. The lancet Oncology, 7, 903–909. https://doi.org/10.1016/S1470-2045(06)70910-X
doi: 10.1016/S1470-2045(06)70910-X pubmed: 17081915
Laugsand, E. A., Sprangers, M. A. G., Bjordal, K., et al. (2010). Health care providers underestimate symptom intensities of cancer patients: A multicenter European study. Health and Quality of Life Outcomes, 8, 104. https://doi.org/10.1186/1477-7525-8-104
doi: 10.1186/1477-7525-8-104 pubmed: 20858248 pmcid: 2949821
EMA. (2018). Regulatory guidance for the use of health-related quality life (HRQL) measures in evaluation medicinal products – Scientific guideline. In: Eur. Med. Agency. https://www.ema.europa.eu/en/regulatory-guidance-use-health-related-quality-life-hrql-measures-evaluation-medicinal-products . Accessed 28 June 2023.
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. (2006). Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims: Draft guidance. Health and Quality of Life Outcomes, 4, 79. https://doi.org/10.1186/1477-7525-4-79
doi: 10.1186/1477-7525-4-79
NICE health technology evaluations: the manual
Cherny, N. I., Sullivan, R., Dafni, U., et al. (2016). ESMO – Magnitude of clinical benefit scale V.1.0 questions and answers. ESMO Open, 1, e000100. https://doi.org/10.1136/esmoopen-2016-000100
doi: 10.1136/esmoopen-2016-000100 pubmed: 27900206 pmcid: 5115817
Wild, D., Grove, A., Martin, M., et al. (2005). Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: Report of the ISPOR task force for translation and cultural adaptation. Value Health, 8, 94–104. https://doi.org/10.1111/j.1524-4733.2005.04054.x
doi: 10.1111/j.1524-4733.2005.04054.x pubmed: 15804318
Papadakos, J. K., Charow, R. C., Papadakos, C. J., et al. (2019). Evaluating cancer patient-reported outcome measures: Readability and implications for clinical use. Cancer, 125, 1350–1356. https://doi.org/10.1002/cncr.31928
doi: 10.1002/cncr.31928 pubmed: 30620401
NIH. (2015). Clear & simple. In: Natl. Inst. Health NIH. https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/clear-communication/clear-simple . Accessed 23 Feb 2023.
Weiss, B. D. (2003). Health literacy a manual for clinicians. http://lib.ncfh.org/pdfs/6617.pdf . Accessed 27 July 2022.
Sørensen, K., Pelikan, J. M., Röthlin, F., et al. (2015). Health literacy in Europe: Comparative results of the European health literacy survey (HLS-EU). European Journal of Public Health, 25, 1053–1058. https://doi.org/10.1093/eurpub/ckv043
doi: 10.1093/eurpub/ckv043 pubmed: 25843827 pmcid: 4668324
20 % de la population dispose d’un diplôme supérieur à bac + 2 – Centre d’observation de la société. https://www.observationsociete.fr/education/donnees-generales/population-par-diplome/ . Accessed 28 July 2023.
Ousseine, Y. M., Bouhnik, A.-D., & Mancini, J. (2022). Health literacy and clinical trial participation in French cancer patients: A national survey. Current Oncology, 29, 3118–3129. https://doi.org/10.3390/curroncol29050253
doi: 10.3390/curroncol29050253 pubmed: 35621643 pmcid: 9140004
Di Meglio, A., Havas, J., Gbenou, A. S., et al. (2022). Dynamics of long-term patient-reported quality of life and health behaviors after adjuvant breast cancer chemotherapy. Journal of Clinical Oncology, 40, 3190–3204. https://doi.org/10.1200/JCO.21.00277
doi: 10.1200/JCO.21.00277 pubmed: 35446677 pmcid: 9509127
Vaz-Luis, I., Cottu, P., Mesleard, C., et al. (2019). UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO). ESMO Open, 4, e000562. https://doi.org/10.1136/esmoopen-2019-000562
doi: 10.1136/esmoopen-2019-000562 pubmed: 31555487 pmcid: 6735667
Lapidari, P., Havas, J., Presti, D., et al. (2022). Abstract P3–12–12: ATTITUDE: Understanding and reducing ATTrition in longiTUDinal studiEs of cancer survivors. Cancer Res, 82, P3-12. https://doi.org/10.1158/1538-7445.SABCS21-P3-12-12
doi: 10.1158/1538-7445.SABCS21-P3-12-12
Zebrack, B. J., Ganz, P. A., Bernaards, C. A., et al. (2006). Assessing the impact of cancer: Development of a new instrument for long-term survivors. Psycho-Oncology, 15, 407–421. https://doi.org/10.1002/pon.963
doi: 10.1002/pon.963 pubmed: 16097041 pmcid: 3731126
Beck, A. T., Guth, D., Steer, R. A., & Ball, R. (1997). Screening for major depression disorders in medical inpatients with the Beck Depression Inventory for Primary Care. Behaviour Research and Therapy, 35, 785–791. https://doi.org/10.1016/s0005-7967(97)00025-9
doi: 10.1016/s0005-7967(97)00025-9 pubmed: 9256522
Beck, A. T., & Steer, R. A. (1984). Internal consistencies of the original and revised Beck Depression Inventory. Journal of Clinical Psychology, 40, 1365–1367. https://doi.org/10.1002/1097-4679(198411)40:6%3c1365::aid-jclp2270400615%3e3.0.co;2-d
doi: 10.1002/1097-4679(198411)40:6<1365::aid-jclp2270400615>3.0.co;2-d pubmed: 6511949
Bull, F. C., Maslin, T. S., & Armstrong, T. (2009). Global physical activity questionnaire (GPAQ): Nine country reliability and validity study. Journal of Physical Activity & Health, 6, 790–804. https://doi.org/10.1123/jpah.6.6.790
doi: 10.1123/jpah.6.6.790
Aaronson, N. K., Ahmedzai, S., Bergman, B., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365–376. https://doi.org/10.1093/jnci/85.5.365
doi: 10.1093/jnci/85.5.365 pubmed: 8433390
Sprangers, M. A., Groenvold, M., Arraras, J. I., et al. (1996). The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study. J Clin Oncol Off J Am Soc Clin Oncol, 14, 2756–2768. https://doi.org/10.1200/JCO.1996.14.10.2756
doi: 10.1200/JCO.1996.14.10.2756
Weis, J., Tomaszewski, K. A., Hammerlid, E., et al. (2017). International psychometric validation of an EORTC quality of life module measuring cancer related fatigue (EORTC QLQ-FA12). Journal of the National Cancer Institute, 109, djw273. https://doi.org/10.1093/jnci/djw273
doi: 10.1093/jnci/djw273
Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scand., 67, 361–370. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x
doi: 10.1111/j.1600-0447.1983.tb09716.x
Ware, J., Kosinski, M., & Keller, S. D. (1996). A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Medical Care, 34, 220–233. https://doi.org/10.1097/00005650-199603000-00003
doi: 10.1097/00005650-199603000-00003 pubmed: 8628042
Scheier, M. F., Carver, C. S., & Bridges, M. W. (1994). Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): A reevaluation of the Life Orientation Test. Journal of Personality and Social Psychology, 67, 1063–1078. https://doi.org/10.1037//0022-3514.67.6.1063
doi: 10.1037//0022-3514.67.6.1063 pubmed: 7815302
Élaboration d’un document écrit d’information à l’intention des patients et des usagers du système de santé. In: Haute Aut. Santé. https://www.has-sante.fr/jcms/c_430286/fr/elaboration-d-un-document-ecrit-d-information-a-l-intention-des-patients-et-des-usagers-du-systeme-de-sante . Accessed 24 Feb 2023.
Friedman, D. B., & Hoffman-Goetz, L. (2006). A systematic review of readability and comprehension instruments used for print and web-based cancer information. Health Education & Behavior, 33, 352–373. https://doi.org/10.1177/1090198105277329
doi: 10.1177/1090198105277329
Conquet, A., & Richaudeau, F. (1973). Cinq méthodes de mesure de la lisibilité. Commun Lang, 17, 5–16. https://doi.org/10.3406/colan.1973.3978
doi: 10.3406/colan.1973.3978
U.S. Department of Health and Human Services, Centers for Medicare & Medicaid Services Using readability formulas: A cautionary note. https://www.montefiore.org/documents/ToolkitPart07.pdf . Accessed 28 July 2023.
The Patient Education Materials Assessment Tool (PEMAT) and User’s Guide. https://www.ahrq.gov/health-literacy/patient-education/pemat.html . Accessed 24 Feb 2023.
Clerehan, R., Guillemin, F., Epstein, J., & Buchbinder, R. (2016). Using the evaluative linguistic framework for questionnaires to assess comprehensibility of self-report health questionnaires. Value Health, 19, 335–342. https://doi.org/10.1016/j.jval.2016.01.008
doi: 10.1016/j.jval.2016.01.008 pubmed: 27325325
Clerehan, R., Hirsh, D., & Buchbinder, R. (2009). Medication information leaflets for patients: The further validation of an analytic linguistic framework. Communication & Medicine, 6, 117–127.
doi: 10.1558/cam.v6i2.117
Hasannejadasl, H., Roumen, C., Smit, Y., et al. (2022). Health literacy and eHealth: Challenges and strategies. JCO Clinical Cancer Informatics e2200005. https://doi.org/10.1200/CCI.22.00005
Kuliś, D., Bottomley, A., Velikova, G., Greimel, E., & Koller M. (2017). EORTC quality of life group translation procedure. https://www.eortc.org/app/uploads/sites/2/2018/02/translation_manual_2017.pdf . Accessed 13 Dec 2023.
Cocks, K., Wells, J. R., Johnson, C., et al. (2023). Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer. European Journal of Cancer, 178, 128–138. https://doi.org/10.1016/j.ejca.2022.10.026
doi: 10.1016/j.ejca.2022.10.026 pubmed: 36436330
Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe | EUonQoL | Project | Fact sheet | HORIZON | CORDIS | European Commission. https://cordis.europa.eu/project/id/101096362 . Accessed 27 July 2023.
Readability Formulas | Free readability assessment tools. https://readabilityformulas.com/ . Accessed 21 Dec 2023.

Auteurs

Camila Chiodi (C)

Cancer Survivorship Group, Inserm Unit 981 Gustave Roussy, Villejuif, France. camilakchiodi@gmail.com.

Jonathan Epstein (J)

Université de Lorraine, APEMAC, Nancy, France.
REFLIS, Paris, France.
French National Platform Quality of Life and Cancer, Paris, France.

Johanna Arvis (J)

Cancer Survivorship Group, Inserm Unit 981 Gustave Roussy, Villejuif, France.

Elise Martin (E)

Cancer Survivorship Group, Inserm Unit 981 Gustave Roussy, Villejuif, France.

Aude Barbier (A)

Cancer Survivorship Group, Inserm Unit 981 Gustave Roussy, Villejuif, France.

Antonio Di Meglio (A)

Cancer Survivorship Group, Inserm Unit 981 Gustave Roussy, Villejuif, France.

Emma Gillanders (E)

Cancer Survivorship Group, Inserm Unit 981 Gustave Roussy, Villejuif, France.

Guillemette Jacob (G)

Seintinelles, Paris, France.

Gwenn Menvielle (G)

Cancer Survivorship Group, Inserm Unit 981 Gustave Roussy, Villejuif, France.

Sibille Everhard (S)

UNICANCER, Paris, France.

Francis Guillemin (F)

Université de Lorraine, APEMAC, Nancy, France.
REFLIS, Paris, France.
French National Platform Quality of Life and Cancer, Paris, France.

Ines Vaz Luis (IV)

Cancer Survivorship Group, Inserm Unit 981 Gustave Roussy, Villejuif, France.
Department for the Organization of Patient Pathways (DIOPP), Inserm Unit 981 Gustave Roussy, Villejuif, France.

Maria Alice Franzoi (MA)

Cancer Survivorship Group, Inserm Unit 981 Gustave Roussy, Villejuif, France.

Classifications MeSH